{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["Salinas CA"],"funding":["Eli Lilly and Company"],"pubmed_abstract":["Introduction
The aim of this work is to evaluate baricitinib safety with respect to venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious infection relative to tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA).Methods
Patients with RA from 14 real-world data sources (three disease registries, eight commercial and three government health insurance claims databases) in the United States (n = 9), Europe (n = 3), and Japan (n = 2) were analyzed using a new user active comparator design. Propensity score matching (1:1) controlled for potential confounding. Meta-analysis of incidence rate ratios (IRR) and incidence rate differences (IRD) for each outcome, from each data source was executed using modified Poisson reg"],"journal":["Rheumatology and therapy"],"pagination":["201-223"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9660195"],"repository":["biostudies-literature"],"pubmed_title":["Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases."],"pmcid":["PMC9660195"],"pubmed_authors":["Bosan R","Louder A","Mai X","B023 Study Consortium","Foster N","Tanaka Y","Kishimoto M","Song Y","Deberdt W","Polinski J","Salinas CA","Doherty BT","Fischer P","Phillips S","Faries D","Zhu B","Thurin NH","Grelaud A","Askling J","Zhang TC","Rashidi E","Chang HC","Gershenson B","Yamanaka H","Bower H"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases.","description":"Introduction
The aim of this work is to evaluate baricitinib safety with respect to venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious infection relative to tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA).Methods
Patients with RA from 14 real-world data sources (three disease registries, eight commercial and three government health insurance claims databases) in the United States (n = 9), Europe (n = 3), and Japan (n = 2) were analyzed using a new user active comparator design. Propensity score matching (1:1) controlled for potential confounding. Meta-analysis of incidence rate ratios (IRR) and incidence rate differences (IRD) for each outcome, from each data source was executed using modified Poisson reg","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-05-31T23:01:17.608Z","creation":"2024-11-20T15:22:17.36Z"},"accession":"S-EPMC9660195","cross_references":{"pubmed":["36371760"],"doi":["10.1007/s40744-022-00505-1"]}}